Cannabis plants produce more than 120 different cannabinoids, but only delta‑9‑tetrahydrocannabinol (THC) and cannabidiol (CBD) have been widely studied and commercialized. Minor cannabinoids are the dozens of compounds present in smaller amounts. These molecules were once mere footnotes in cannabis chemistry, but a surge of consumer curiosity, product innovation, and scientific interest is bringing them into the spotlight. The legalization of hemp-derived products in the United States and shifting global attitudes have opened a market where minor cannabinoids are now sold as tinctures, gummies, and vape cartridges. At the same time, the scientific literature is struggling to keep pace with their emergence. This article unpacks the latest research findings about these compounds.
Minor Cannabinoids and the Latest Evidence
Cannabinoids are classified as major or minor depending on their abundance in the plant. The major cannabinoids (THC and CBD) are typically present at concentrations >1 % of dry flower, whereas most other cannabinoids occur in milligram-per‑gram or microgram‑per‑gram levels. Almost all cannabinoids originate from cannabigerolic acid (CBGA), but because minor cannabinoids are often degradation products or branch‑point intermediates, they historically existed only in trace amounts; however, recent breeding and extraction techniques now make it possible to isolate them in quantities enough for research and commercial use.
Cannabigerol (CBG)
Often called the “mother cannabinoid,” CBG is the direct precursor to THC, CBD, and CBC. Animal studies indicate that CBG has anti‑inflammatory, neuroprotective, and antimicrobial properties. In 2024, researchers at Washington State University conducted a double‑blind, placebo‑controlled crossover trial in 34 healthy adults. Participants received 20 mg of purified CBG or placebo in two sessions separated by a week; outcomes included anxiety, stress, mood, memory, and subjective drug effects. Compared with placebo, CBG significantly reduced anxiety and stress scores and improved verbal memory at early time points without causing intoxication or impairment. The authors concluded that CBG may be anxiolytic and memory‑enhancing, but the trial was small and short‑term. Additionally, CBG production remains expensive because CBGA quickly converts into other cannabinoids, prompting interest in engineered yeast and high‑CBG cultivars.
Cannabichromene (CBC)
CBC is a non‑intoxicating cannabinoid derived from CBCA. Preclinical work suggests that it interacts with cannabinoid receptor 2 (CB2), TRPA1, and other transient receptor potential channels, leading to anti‑inflammatory and analgesic effects. A 2023 study used computational target prediction followed by neuropathic pain models in mice to test CBC’s antinociceptive properties. Mice received 10 or 20 mg/kg CBC and were evaluated in mechanical allodynia (pain from normal, harmless stimuli), tail‑flick, and formalin tests. CBC significantly reduced mechanical allodynia and nociceptive behaviors, indicating potential analgesic activity.
Cannabinol (CBN)
CBN is formed when THC oxidizes over time; aged cannabis products often contain higher CBN levels. Marketing frequently positions CBN as a sedative or “sleep cannabinoid,” but empirical data are mixed. In a 2024 double‑blind, randomized, placebo‑controlled crossover study of 20 adults with insomnia, participants received 20 mg CBN nightly for seven nights. Compared to placebo, CBN reduced the number of nightly awakenings and overall sleep disturbance, but did not significantly shorten sleep onset latency or improve daytime fatigue. Another 2025 rat study examined CBN and its active metabolite 11‑hydroxy‑CBN. CBN increased total sleep time as well as REM and non‑REM sleep; its metabolite displayed CB1 receptor potency comparable to THC, suggesting that metabolic activation contributes to CBN’s effects. These findings support modest sedative effects, but there is no strong evidence that CBN alone is a potent hypnotic. Products combining CBN with melatonin or other sedatives may be more effective, highlighting the need for controlled trials.
Tetrahydrocannabivarin (THCV)
THCV acts as a CB1 antagonist at low doses and a partial agonist at CB2 receptors. Animal studies suggest that THCV suppresses appetite, improves insulin sensitivity, and reduces lipid accumulation. A 2025 mini‑review reported that preclinical models of type 2 diabetes showed improved fasting glucose and beta‑cell function after THCV administration, and that one clinical trial in diabetic patients found THCV lowered fasting plasma glucose and improved beta‑cell function. Other small human trials indicate that THCV may modestly reduce hunger and enhance neural responses to aversive food stimuli, though these effects often lack statistical significance. A pilot study also showed that 10 mg THCV given daily for five days before THC administration reduced THC‑induced tachycardia and memory impairment, and participants subjectively rated THC as weaker. While the evidence hints at metabolic and cognitive benefits, THCV remains expensive to produce and is subject to regulatory ambiguity.
Cannabidivarin (CBDV)
CBDV is the varin analogue of CBD and is non‑intoxicating. Its pharmacokinetics are limited by poor oral bioavailability. Nevertheless, CBDV has attracted pharmaceutical interest for rare epilepsies and neurodevelopmental disorders. A 2022 phase 1 trial enrolled girls with Rett syndrome and drug‑resistant epilepsy and administered 10 mg/kg/day CBDV for 29 days. CBDV was well tolerated; four of five participants experienced a >75 % reduction in monthly seizure frequency, and adverse events were mild (hypersomnolence and drooling). These encouraging results spurred ongoing trials for autism spectrum disorder and focal seizures.
Delta‑8 THC and Other Emerging Cannabinoids
Delta‑8 THC is a semi‑synthetic isomer of delta‑9 THC. Although delta‑8 is less potent than delta‑9, studies show it can have antiemetic effects that may exceed delta‑9 THC. Neurochemical research indicates that delta‑8 modulates acetylcholine turnover and alters dopamine, serotonin, and norepinephrine levels in various brain regions. These data suggest psychoactive properties not far removed from delta‑9. However, reports of delta‑8 adverse events were three times higher than those for delta‑9 THC. Consumers should therefore approach delta‑8 products with caution. Other emerging cannabinoids, such as cannabigerolic acid (CBGA), cannabichromenic acid (CBCA), and tetrahydrocannabinolic acid (THCA), remain largely unstudied. Scientists are beginning to explore these acids for their potential anti‑inflammatory or neuroprotective roles.
How Are Producers Harnessing Minor Cannabinoids?
Minor cannabinoids promise targeted and personalized formulations. Pharmacogenetic research shows that genetic differences in cannabinoid receptors and metabolizing enzymes influence individual responses; understanding those differences could allow producers to tailor cannabinoid therapies. Additionally, minor cannabinoids interact differently with the endocannabinoid system, offering possibilities for formulations that address specific conditions (e.g., THCV for metabolic disorders or CBN for sleep). A recent review on medical cannabis emphasized that to mitigate variability and side effects, cannabis products need standardized cannabinoid profiles; advances in cultivation, such as selective breeding and genetic engineering, could help produce plants with stable profiles. And now, there are improved extraction and chromatographic isolation techniques that allow producers to separate and concentrate these molecules at a reasonable cost. The U.S. cannabinoid market was valued at USD 18.14 billion in 2022 and is projected to grow at an annual rate of 15.3 % from 2023–2030, with CBG, CBN, and CBDV identified as promising compounds. These figures illustrate how economic momentum is dovetailing with scientific curiosity.
Consumer Interest and Market Trends
The 2018 U.S. Farm Bill legalized hemp cultivation and the sale of hemp‑derived cannabinoids, catalyzing an explosion of minor cannabinoid products at dispensaries, vape shops, and even gas stations. To understand how consumers are engaging with these products, researchers from Colorado Chromatography Labs conducted an anonymous survey of 105 consumers and published the results in 2025. Respondents indicated that CBD, delta‑8 THC, and CBN were the most frequently used cannabinoids, and vapes and edibles were the preferred delivery methods. Improved sleep, pain relief, and recreation were cited as the primary motivations for use. While 91.4 % of participants considered themselves at least “somewhat knowledgeable,” a striking 71.4 % reported that they always look for third‑party testing results when purchasing products, and more than 87 % considered product safety very important. Respondents were highly concerned about product purity, long‑term effects, and side effects, underscoring the disconnect between consumer enthusiasm and scientific uncertainty. Broader surveys support the idea that many cannabis users rely on informal information sources. A nationally representative 2024 survey of 1,161 adults found that friends/family (35.6 %) and websites (33.7 %) were the most common sources of cannabis information, while only 9.3 % consulted a health‑care provider. Past‑year cannabis users were significantly more likely to use all information sources except government agencies. The authors concluded that as cannabis becomes more accessible, there is a strong need for better clinician education and public health outreach. The popularity of minor cannabinoids thus reflects both genuine curiosity about novel therapeutic options.
Quality and Regulatory Considerations
Product purity and accurate labeling are major concerns with minor cannabinoids. A 2025 liquid chromatography study analyzed 56 CBD gummy products purchased in the U.S. and found that 70 % of products differed by more than 10 % from the labeled amount. Additionally, 39 % of gummies contained delta‑9 THC (0.019–0.88 mg per gummy), and 16 % contained more than 0.4 mg THC per gummy, levels that could be intoxicating. High variability within bottles suggested poor manufacturing controls. Another survey of 80 unregulated hemp‑derived oil products found that none of the labels disclosed these minor cannabinoid concentrations. These findings indicate that consumers often ingest unknown combinations and doses of cannabinoids. Legal ambiguity exacerbates these issues. Patchwork regulations exist internationally, making it difficult for researchers to obtain consistent products and for consumers to know what they are buying. Regulatory agencies are beginning to respond; some states now require potency testing and labeling for minor cannabinoids, and federal discussions about rescheduling cannabis may eventually lead to stricter oversight.
Conclusion
Minor cannabinoids represent an exciting frontier in cannabis science. Compounds like CBG, CBC, CBN, THCV, and CBDV exhibit diverse pharmacological profiles and early evidence of therapeutic potential ranging from anxiety reduction to seizure control. At the same time, unregulated products and incomplete research create a landscape where hype often outpaces science. Controlled trials, standardized production, pharmacogenetic research, and transparent regulation are essential to unlock the benefits of these molecules while safeguarding public health. Through rigorous science and responsible regulation, minor cannabinoids may soon move from novelty items to validated therapeutic tools.